Next Article in Journal
From Bite to Recovery: Safety and Efficacy of Pan-African Polyvalent Antivenom Used for Treating Snakebites in Cameroon
Next Article in Special Issue
Editorial: Introduction to the Toxins Special Edition Honoring Dr. John D. Groopman for His Contributions to the Field of Aflatoxin Carcinogenesis Research
Previous Article in Journal
Aligning Minds in Spasticity Care—A Two-Phase Delphi-Dialogue Study of Patients and Professionals in Spain
Previous Article in Special Issue
The Difficulties in Demonstrating That Aflatoxin Reduction Improves Stunting in Developing World Regions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 18
Issue 1
10.3390/toxins18010058
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Aflatoxin Exposure and Human Health with a Focus on Northern Latin America

by
Karen A. Corleto
1,2,
Christian S. Alvarez
3,
Manuel Ramirez-Zea
4,
John D. Groopman
5 and
Katherine A. McGlynn
2,*
1
Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20850, USA
2
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA
3
Division of Intramural Research, National Institute on Minority Health and Health Disparities, Rockville, MD 20852, USA
4
Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central America and Panama, Guatemala City 1188, Guatemala
5
Departments of Environmental Health and Engineering and Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
*
Author to whom correspondence should be addressed.
Toxins 2026, 18(1), 58; https://doi.org/10.3390/toxins18010058
Submission received: 5 November 2025 / Revised: 13 January 2026 / Accepted: 15 January 2026 / Published: 22 January 2026
(This article belongs to the Special Issue 65 Years On from Aflatoxin Discovery—a Themed Issue in Honor of Professor John D. Groopman)
Browse Figure
Versions Notes

Abstract

Aflatoxins, mycotoxins produced by Aspergillus flavus and Aspergillus parasiticus, were discovered sixty-five years ago and remain a significant public health threat, particularly amid increasing instances of extreme weather events. Of the four principal forms of aflatoxins found in foods (B1, B2, G1, and G2), aflatoxin B1 is the most potent carcinogen. Aflatoxins commonly contaminate a variety of foodstuffs, with maize being among the most susceptible. Chronic exposure to aflatoxins has been linked to liver cancer, childhood stunting, gallbladder cancer, and other adverse health effects. Due to public health concerns related to the consumption of aflatoxin-contaminated foods, most countries have established regulatory limits. Here, we present estimated aflatoxin exposure per day derived from human biomarker data across many studies around the world spanning more than forty years. We specifically focus on the impact of dietary aflatoxin in northern Latin America, where assessment of the total problem remains limited. These findings suggest a multipronged toolkit could mitigate aflatoxin exposure in the region, which would help to decrease the health burden.
Keywords:
aflatoxin; maize; liver cancer; Latin America
Key Contribution: Aflatoxin contamination of food items is well-known to be a major health threat in parts East Asia and sub-Saharan Africa. Less well-appreciated is the role that aflatoxin may play in Latin American countries that consume high levels of maize.

1. Introduction

Aflatoxins, identified as disease-causing mycotoxins sixty-five years ago [1,2], continue to be significant public health issues due to their toxic, mutagenic, and carcinogenic properties [3]. Primarily produced by the fungi Aspergillus flavus and Aspergillus parasiticus [4,5], approximately twenty aflatoxins have been described [2], but the four principal forms that dominate human exposure are aflatoxin B1 (AFB1), B2 (AFB2), G1 (AFG1), and G2 (AFG2) [4]. Of these forms, AFB1 is the major aflatoxin driving health concerns [6].
Although other routes of exposure occur, human exposure to AFB1 occurs predominantly through the consumption of contaminated foods. Various foodstuffs have tested positive for aflatoxin contamination, including spices, pulses, beans, tea, cocoa, milk, grains, and groundnuts [3,6,7]. The major sources of aflatoxin in the human diet, however, are maize, groundnuts and other grains [4,6,8]. AFB1 contamination can be challenging to combat as it can develop both pre- and post-harvest, with weather conditions including rainfall, temperature, and humidity converging to produce environmental conditions optimal for mold growth [6,8].
Due to widespread environmental contamination by aflatoxins and the negative health implications for both humans and other animal species, a number of countries have established regulatory limits on aflatoxins in foodstuffs, but there is no global consensus on regulatory standards.

2. Regulatory Limits on Aflatoxins

Regulatory limits for aflatoxins vary widely by country and food item. For example, the European Union (EU) regulations are some of the most stringent, with limits for both total aflatoxins (4–15 parts per billion, ppb), and for AFB1 (2–12 ppb) [9]. The EU regulations vary by commodity but are most strict for ready-to-eat foods. In contrast, the United States has only one limit (20 ppb) for all food items [10], while Mexico has a limit of 20 ppb for maize grain but a lower level (12 ppb) for nixtamalized maize products [11,12]. Guatemala also has a limit of 20 ppb (total aflatoxins) for maize and maize products [12,13].
Despite the existence of regulatory limits, aflatoxin contamination remains a concern in many countries. A risk assessment that evaluated the effectiveness of aflatoxin regulatory standards in protecting against liver cancer concluded that most standards limited lifetime risk to below 1 case per 10,000 individuals [14]. However, the report also found that in some parts of Latin America, regulatory standards did not meet this level of protection [14]. In addition, regulatory standards are only effective if they are enforced and many countries lack the capacity to do so.
Table 1 shows the estimated intake of total aflatoxins depending on the regulatory standard and the grams of a dietary item consumed. To calculate daily aflatoxin exposure, 3% of the intake of contaminated food was used to estimate AFB1 µg/day. The calculation assumes a steady state of adduct accumulation over 30 days, as previous work indicates that 2.9% of the daily dietary exposure is converted to the aflatoxin albumin adduct.

3. Evaluating Aflatoxin Exposure

While global exposure to aflatoxins from contaminated foods is well documented, estimating the putative dose to humans has been a goal of aflatoxin biomarker research. Knowledge of the metabolism and formation of specific covalent aflatoxin adducts in DNA and proteins has been deployed in many epidemiologic studies. In recent years the recognition that the aflatoxin-lysine adduct formed in albumin is an integrative biomarker of exposure has been of great significance in the field [15]. To put the AFB1 levels in northern Latin America in context, Table 2 summarizes studies of Groopman and colleagues of AFB1-lys adduct levels and converts those levels to estimated daily aflatoxin exposure in µg, using the formula mentioned above [16,17].
As seen in Table 2, the lowest mean daily aflatoxin exposure (0.01 ± 0.02 µg/day) seen in these studies was in 2012 in Qidong, China. This low level was achieved after the implementation in Qidong of the switch in dietary staple from maize to rice. In comparison, the highest exposure (91.1 ± 201.42 µg/day) in Table 2 occurred during an outbreak of acute aflatoxicosis in Kenya in 2004 [33,34,35]. Figure 1 displays the results of many of these studies plotted side by side.

4. Maize Consumption as a Vehicle for Aflatoxin Exposure

In northern Latin America, maize has been a dietary staple for millenia. Numerous foods, such as tortillas, tamales, gorditas, and pupusas, are made from nixtamalized maize flour, which is maize grain that has been cooked in a solution of calcium hydroxide prior to being ground [38,39,40]. Environmental conditions (temperature, humidity, and rainfall) in the region can facilitate pre- and post-harvest AFB contamination [3]. Extreme weather events, including droughts and unseasonal rains, further increase the risk of AFB contamination, and rising temperatures and humidity are projected to enhance pre-harvest aflatoxin contamination of susceptible crops [8,41].
Of the food items made from maize, tortillas are consumed in the greatest quantity. For example, in Veracruz City, Mexico, reports indicate that tortilla intake averages 118.4 g (person/day) [42]. In a recent report from Mexico that evaluated maize consumption using the country’s National Health and Nutrition Survey (ENSANUT), the median intake of maize was 307 g/d, mainly attributed to tortilla intake (77%) [29]. The high consumption of tortillas is of particular concern as tortillas have been demonstrated by several studies to be contaminated with AFB. In the Mexican state of San Luis Potosí, an evaluation of tortillas revealed that 18% of the samples exceeded Mexico’s limit (12 ppb) for AFB1 [43], while in Mexico City, 4.5% of nixtamalized maize samples were reported to have detectable levels of aflatoxins [39].
In Guatemala, a cross-sectional evaluation of 461 adults found median AFB1 levels of 7.5 pg/mg albumin among women and 11.4 pg/mg albumin among men [44]. For reference, a level of 17.5 pg/mg albumin is an adduct burden arising from a daily exposure to 1 µg AFB1 per day for 30 days [17]. In the cross-sectional study, the median AFB1 levels were higher among individuals in rural areas (14.0 pg/mg albumin) than in urban areas (4.9 pg/mg) [44]. The study also found a significant relationship between tortilla consumption and levels of AFB1-albumin adducts [45]. A separate study of Guatemalan women who worked as tortilla makers reported an average weekly consumption of maize to be 3470.5 g, primarily in the form of tortillas. Tortilla sampling found that 11% had detectable levels AFB1 [46]. In a study from Honduras, 65% of maize and maize products were contaminated with aflatoxin, with the mean total aflatoxins ranging from 1.06 µg/kg to 6.23 µg/kg [47].
A 2014 examination of global maize consumption estimated that the highest levels of consumption in the western hemisphere were in Mexico (267 g/person/day), Guatemala (187 g/person/day), and Honduras (169 g/person/day) [48]. Thus, with the aflatoxin regulatory limit in Mexico of 20 ppb (20 µg per kg), the consumption of 267 g/person/day in Mexico would result in an aflatoxin exposure of roughly 3.2 µg/day. A similar calculation for Guatemala results in an aflatoxin exposure of roughly 3.7 µg/day. In addition, localized reports from many areas have found that maize products are being consumed at a level of more than 260 g/day [29,45,46,47]. These data indicate that contamination levels in several regions exceed the regulatory limits, making these regulations insufficient/ineffective to protect human health.

5. Health Burden of Aflatoxin Exposure in Latin America

Aflatoxin has been associated with a number of health-related conditions, with liver cancer, after acute aflatoxicosis, being one of the most fatal. Liver cancer is the sixth most commonly diagnosed cancer worldwide and the third largest contributor to cancer mortality [49]. The relationship between aflatoxin exposure and liver cancer is well documented, leading the International Agency for Research on Cancer to classify aflatoxin as a group 1 human carcinogen [5,17,50,51,52,53]. In Latin America, while there are few established cancer registries, it is estimated that Guatemala has the highest age-standardized liver cancer incidence rate (15.5 per 100,000 persons) in the western hemisphere [24]. In contrast, the age-standardinzed liver cancer incidence rate in the U.S. is 6.8/100,000 persons
Aflatoxin is not only a risk factor itself but can be an even more potent risk factor when it co-occurs with other factors, including alcohol, obesity, and type II diabetes, as well as chronic infections with hepatitis C virus and hepatitis B virus (HBV) [24,54,55,56,57]. The synergism between aflatoxin and HBV was well demonstarted in a study conducted in Shanghai, China, that found the risk of liver cancer was 3.4-fold higher among persons exposed to AFB1, 7-fold higher among persons who were HBV(+), and 59-fold higher among persons with both factors [58]. This synergistic relationship was also subsequently observed in other cohorts [51]. In Latin America, HBV prevalence estimates tend to be lower than in other areas of the world, although comprehensive prevalence data for the region are very limited [59]. For example, a study conducted in Guatemala that examined both aflatoxin and HBV found that the prevalence of aflatoxin was high but the prevalence of HBV was low [22,23,24].
Although HBV may not play a significant role in liver cancer in Latin America, factors such as obesity and type II diabetes [24,57] may also increase the risk of liver cancer among persons exposed to aflatoxin. In Latin America, it is estimated that 30.5% of adults live with obesity, and 64% are overweight [60]. With the increase in obesity rates, type II diabetes has also increased, with estimates that in the next 20 years there will be a 50% increase in type II diabetes in the region [60]. Obesity and type II diabetes also are risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD), which itself is a risk factor for liver cancer [61]. In Guatemala, a study reported a significant association between AFB1-albumin adduct levels and diabetes [44]. Although the mechanism by which AFB1 increases risk of diabetes is uncertain, the relationship may be due to AFB1 causing inflammation and oxidative stress, impairing insulin secretion and disrupting carbohydrate metabolism. More research is needed to improve the understanding of the relationship between aflatoxins, metabolic disorders, and other factors in affecting liver cancer risk in Latin America.
In addition to liver cancer and metabolic disorders, aflatoxin has been associated with childhood stunting, both independently and in conjunction with other risk factors [4]. Hypotheses on the mechanism by which aflatoxin influences stunting include impairment of the immune system, effects on the IGF-1 axis, and an effect on environmental enteric dysfunction (EED) [4,62]. Among Latin American countries, Guatemala has a notably high level of stunting, with a prevalence ≥ 40% [62], and aflatoxin exposure has been negatively correlated with child height-for-age-z-scores [63]. A cross-sectional study conducted in low-income African countries found that children with both stunting and underweight had the highest levels of aflatoxin albumin adducts as measured by enzyme-linked immunosorbent assay (ELISA) (132.27 pg/mg albumin), followed by children with stunting alone (109.41 pg/mg albumin), followed by children without stunting (75.01 pg/mg albumin) [64]. In addition, a study in Malawi that used mass spectrometry reported that aflatoxin exposure was negatively associated with child growth [65]. Collectively, a published paired study can be used to interconvert data from ELISA with mass spectrometry-derived aflatoxin albumin adducts [25].
Other health-related conditions have also been linked to chronic dietary exposure to aflatoxins. It has been suggested that aflatoxins may influence innate and adaptive immunity [54,66], with some human studies providing evidence that aflatoxin can have immunosupressive effects in children and adults [67,68]. Gambian children with higher exposure to aflatoxin had reduced levels of the antibody secretory IgA in their saliva [67]. In adults from Ghana it was found that aflatoxin exposure influences cellular immune status [68]. Further research, particularly in human populations, is required to better understand how aflatoxin exposure affects immunity. Perhaps the results of studies of aflatoxin exposure and oncogenic human papillomaviruses (HPV) are related to effects on the immune system. Studies in both Kenya and Mexico have indicated an association between aflatoxin and oncogenic HPV in women [27,28,69,70]. Aflatoxin exposure may also be related to the development of gallbladder cancer, as reported by studies conducted in Chile and Shanghai [36,37,71,72]. There are also investigations into how aflatoxin-induced oxidative stress and reductions in nuerotransmitter levels may impact neurogenerative disease [54,73].

6. Toolkit of Interventions to Tackle Aflatoxin Exposure in Latin America

The regulation of aflatoxins in food and the strict enforcement of those regulations are critical components of a primary prevention approach to aflatoxin control. In conjunction with regulatory standards, aflatoxin urinary and blood biomarkers should be used to monitor exposure, providing a metric of the efficacy of the regulatory standards. Urinary biomarkers (AFB1, AFM1, and AFB1-N7-Gua DNA-adduct) are suitable for measuring short-term exposure [58,74], while serum AFB1-lys adduct levels are the best estimates of longer-term exposure. In humans, the average lifetime for albumin is approximately thirty days [75]. Therefore, albumin adduct formation provides a more comprehensive picture of aflatoxin exposure that estimates average aflatoxin exposure per day over a 30-day period. Using AFB1 metabolites to estimate daily aflatoxin exposure in Latin America would be an effective tool to monitor acute exposure or the average daily exposure over a longer time at the individual or population level. Effect monitoring programs could help governments gauge the effectiveness of regulatory measures and aid in making informed decisions about aflatoxin control. To most effectively conduct a monitoring program, there is a demonstrable need for capacity building and infrastructure development to establish aflatoxin monitoring laboratories throughout Latin America.
Due to the importance of preventing crop contamination from aflatoxins, pre-harvest contamination prediction models have been developed [76,77]. The most recent models use a meteorology-driven epidemiological approach, such as the model described by Stutt and colleagues that encompasses the maize supply chain from planting to delivery [76]. Biological control is also a possible approach to pre-harvest aflatoxin management. Some of the pre-harvest techniques include competitive exclusion using non-aflatoxigenic strains and microbial bio-fungicides [2,3,78,79,80]. During postharvest, proper drying, including such strategies as controlled environment drying, sun drying on platforms, and removing damaged corn, can aid in the reduction of aflatoxin contamination [12]. Field drying of maize under humid conditions in Mexico and northern Central America can result in moisture levels (14–18%), which are higher than the recommended range to reduce aflatoxin contamination (12–14%) [12]. Adequate storage with low humidity and temperature conditions also helps to minimize fungal growth [12].
In addition to pre- and post-harvest strategies for aflatoxin reduction, cooking can also reduce the amount of aflatoxin in foods. Roasting at high temperatures has been shown to decrease aflatoxin levels 50–90% [81]. Boiling can also be an effective strategy, as boiling rice at 100 °C for 12 min has been reported to decrease aflatoxin levels [82]. In Mexico and Central America, nixtamalization of maize is a common practice, and most maize products consumed are nixtamalized [12,39,45,83]. While some studies have found that nixtamalization reduced aflatoxin by 88% (44.99 ppb to 5.26 ppb) [38], the process is not entirely successful as aflatoxin contamination continues to be an issue in Latin America.
While primary prevention is always the optimal strategy, secondary prevention strategies, such as chemoprevention to detoxify consumed aflatoxins, have been proposed. AFB1 is bioactivated into aflatoxin-8,9-epoxide (AFBO), the metabolite that reacts with DNA to form adducts. To interrupt adduct formation, phase II metabolism then plays an important role in detoxification. Glutathione S-transferases conjugate glutathione to AFBO to facilitate eventual excretion in urine [52,84]. Agents that promote the induction of glutathione S-transferases can therefore assist in the detoxification process. Two agents that have shown a positive effect on glutathione S-transferase induction are the pharmaceutical Oltipraz and a natural compound found in cruciferous vegetables, sulforaphane [85,86,87]. In a placebo-controlled trial, Oltipraz at a dose of 500 mg taken weekly for one month was demonstrated to decrease median urinary levels of the metabolite AFM1 by 51% [87,88]. In a study of sulforaphane, 2 weeks of broccoli sprout infusion resulted in modest decreases in urinary levels of aflatoxin N7-guanine [85]. In the study, there was high variability among individuals in sulforaphane levels, which correlated with decreases in aflatoxin N7-guanine [85]. Other bioactive compounds that have shown promising results are polyphenols from curcumin and green tea [84,89]. To our knowledge, these secondary chemoprevention strategies have not yet been tried in Latin America.

7. Conclusions

Aflatoxins threaten human health in a myriad of ways across the lifespan. The carcinogenic effects of AFB1 on the liver are of particular concern. In addition, the effects on childhood stunting, oncogenic HPV infection, and gallbladder cancer are of significant concern in areas where contamination is common. Due to fluctuating environmental conditions, this aflatoxin contamination could greatly increase. There is a strong need to implement effective aflatoxin monitoring systems, in areas such as Latin America, where staple dietary foods such as maize are commonly contaminated. Urinary and blood biomarkers produced during aflatoxin metabolism are useful for monitoring exposure in individuals and for measuring the effectiveness of mitigation strategies. The effectiveness of both pre-harvest and post-harvest techniques can be measured by biomonitoring a population’s daily aflatoxin exposure. The success of secondary prevention methods can also be determined. Overall, the use of aflatoxin biomarker monitoring in Latin America could guide regulatory efforts and assist in making informed decisions on intervention strategies.

Author Contributions

Conceptualization, K.A.C., J.D.G. and K.A.M.; writing—original draft preparation, K.A.C.; writing—review and editing, C.S.A., M.R.-Z., J.D.G. and K.A.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study.

Acknowledgments

The authors wish to thank Alvaro Rivera-Andrade of INCAP, Guatemala City, Guatemala, and the participants of the North American Liver Cancer Study.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Kensler, T.W.; Roebuck, B.D.; Wogan, G.N.; Groopman, J.D. Aflatoxin: A 50-year odyssey of mechanistic and translational toxicology. Toxicol. Sci. 2011, 120, S28–S48. [Google Scholar] [CrossRef]
  2. Pickova, D.; Ostry, V.; Toman, J.; Malir, F. Aflatoxins: History, Significant Milestones, Recent Data on Their Toxicity and Ways to Mitigation. Toxins 2021, 13, 399. [Google Scholar] [CrossRef] [PubMed]
  3. Jallow, A.; Xie, H.; Tang, X.; Qi, Z.; Li, P. Worldwide aflatoxin contamination of agricultural products and foods: From occurrence to control. Compr. Rev. Food Sci. Food Saf. 2021, 20, 2332–2381. [Google Scholar] [CrossRef]
  4. Wild, C.P.; Miller, J.D.; Groopman, J.D. (Eds.) Mycotoxin Control in Low- and Middle-Income Countries; International Agency for Research on Cancer: Lyon, France, 2015; Volume 9.
  5. Liu, Y.; Chang, C.-C.H.; Marsh, G.M.; Wu, F. Population attributable risk of aflatoxin-related liver cancer: Systematic review and meta-analysis. Eur. J. Cancer 2012, 48, 2125–2136. [Google Scholar] [CrossRef]
  6. EFSA Panel on Contaminants in the Food Chain; Schrenk, D.; Bignami, M.; Bodin, L.; Chipman, J.K.; del Mazo, J.; Grasl-Kraupp, B.; Hogstrand, C.; Hoogenboom, L.; Leblanc, J.-C.; et al. Risk assessment of aflatoxins in food. EFSA J. 2020, 18, e06040. [Google Scholar] [CrossRef]
  7. Eskola, M.; Kos, G.; Elliott, C.T.; Hajšlová, J.; Mayar, S.; Krska, R. Worldwide contamination of food-crops with mycotoxins: Validity of the widely cited ‘FAO estimate’ of 25%. Crit. Rev. Food Sci. Nutr. 2020, 60, 2773–2789. [Google Scholar] [CrossRef]
  8. Nji, Q.N.; Babalola, O.O.; Mwanza, M. Climatic effects on aflatoxin contamination of maize. Toxicol. Rep. 2024, 13, 101711. [Google Scholar] [CrossRef]
  9. European Commission. Commission Regulation (EU) 2023/915 of 25 April 2023 on maximum levels for certain contaminants in food and repealing Regulation (EC) No 1881/2006. Off. J. Eur. Union 2023, 119, 103–157. [Google Scholar]
  10. Food and Drug Administration. Compliance Policy Guide Sec. 555.400 Aflatoxins in Human Food: Guidance for FDA Staff; US Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition and Office of Regulatory Affairs: Silver Spring, MD, USA, 2021.
  11. La Moderna, P.A.; De, C.; El Pilar, M.D.T.; De, K.F.D.M.S. ANTEPROYECTO de Norma Oficial Mexicana PROY-NOM-247-SSA1-2005, Productos y Servicios. Cereales y sus Productos. Cereales, Harinas de Cereales, Sémolas o Semolinas. Alimentos a Base de: Cereales, Semillas Comestibles, de Harinas, Sémolas o Semolinas o sus Mezclas. Productos de Panificación. Disposiciones y Especificaciones Sanitarias y Nutrimentales. Métodos de Prueba. PREFACIO. Available online: https://platiica.economia.gob.mx/normalizacion/nom-247-ssa1-2008/ (accessed on 4 January 2025).
  12. Odjo, S.; Alakonya, A.E.; Rosales-Nolasco, A.; Molina, A.L.; Muñoz, C.; Palacios-Rojas, N. Occurrence and postharvest strategies to help mitigate aflatoxins and fumonisins in maize and their co-exposure to consumers in Mexico and Central America. Food Control 2022, 138, 108968. [Google Scholar] [CrossRef]
  13. Comisión Guatemalteca de Normas. Maíz en Grano. Maíz Elaborado. NGO 34 047 1982. Available online: https://cretec.org.gt/wp-content/uploads/2021/03/ngo34047maizelaborado.pdf (accessed on 4 January 2025).
  14. Wu, F.; Stacy, S.L.; Kensler, T.W. Global risk assessment of aflatoxins in maize and peanuts: Are regulatory standards adequately protective? Toxicol. Sci. 2013, 135, 251–259. [Google Scholar] [CrossRef] [PubMed]
  15. Smith, J.W.; Ng, D.K.; Alvarez, C.S.; Egner, P.A.; Burke, S.M.; Chen, J.-G.; Kensler, T.W.; Koshiol, J.; Rivera-Andrade, A.; Kroker-Lobos, M.F.; et al. Assessing the Validity of Normalizing Aflatoxin B1-Lysine Albumin Adduct Biomarker Measurements to Total Serum Albumin Concentration across Multiple Human Population Studies. Toxins 2022, 14, 162. [Google Scholar] [CrossRef]
  16. Sabbioni, G.; Ambs, S.; Wogan, G.N.; Groopman, J.D. The aflatoxin-lysine adduct quantified by high-performance liquid chromatography from human serum albumin samples. Carcinogenesis 1990, 11, 2063–2066. [Google Scholar] [CrossRef] [PubMed]
  17. Chen, J.G.; Kensler, T.W.; Zhu, J.; Zhu, Y.R.; Wang, J.B.; Lu, J.H.; Munoz, A.; Groopman, J.D. Profound primary prevention of liver cancer following a natural experiment in China: A 50-year perspective and public health implications. Int. J. Cancer 2025, 156, 756–763. [Google Scholar] [CrossRef] [PubMed]
  18. Smith, J.W.; Matchado, A.J.; Wu, L.S.; Arnold, C.D.; Burke, S.M.; Maleta, K.M.; Ashorn, P.; Stewart, C.P.; Shaikh, S.; Ali, H.; et al. Longitudinal Assessment of Prenatal, Perinatal, and Early-Life Aflatoxin B1 Exposure in 828 Mother-Child Dyads from Bangladesh and Malawi. Curr. Dev. Nutr. 2022, 6, nzab153. [Google Scholar] [CrossRef] [PubMed]
  19. Mahfuz, M.; Alam, M.A.; Fahim, S.M.; Gazi, M.A.; Raihan, M.J.; Hossain, M.; Egner, P.A.; Bessong, P.O.; Petri, W.A.; Groopman, J.D.; et al. Aflatoxin exposure in children living in Mirpur, Dhaka: Data from MAL-ED companion study. J. Expo. Sci. Environ. Epidemiol. 2019, 29, 655–662. [Google Scholar] [CrossRef]
  20. Mahfuz, M.; Hasan, S.M.T.; Alam, M.A.; Das, S.; Fahim, S.M.; Islam, M.M.; Gazi, M.A.; Hossain, M.; Egner, P.A.; Groopman, J.D.; et al. Aflatoxin exposure was not associated with childhood stunting: Results from a birth cohort study in a resource-poor setting of Dhaka, Bangladesh. Public Health Nutr. 2021, 24, 3361–3370. [Google Scholar] [CrossRef]
  21. Chen, J.G.; Egner, P.A.; Ng, D.; Jacobson, L.P.; Munoz, A.; Zhu, Y.-R.; Qian, G.-S.; Wu, F.; Yuan, J.-M.; Groopman, J.D.; et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev. Res. 2013, 6, 1038–1045. [Google Scholar] [CrossRef]
  22. Alvarez, C.S.; Hernández, E.; Escobar, K.; Villagrán, C.I.; Kroker-Lobos, M.F.; Rivera-Andrade, A.; Smith, J.W.; Egner, P.A.; Lazo, M.; Freedman, N.D.; et al. Aflatoxin B(1) exposure and liver cirrhosis in Guatemala: A case-control study. BMJ Open Gastroenterol. 2020, 7, e000380. [Google Scholar] [CrossRef]
  23. Smith, J.W.; Kroker-Lobos, M.F.; Lazo, M.; Rivera-Andrade, A.; Egner, P.A.; Wedemeyer, H.; Torres, O.; Freedman, N.D.; McGlynn, K.A.; Guallar, E.; et al. Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS ONE 2017, 12, e0189255. [Google Scholar] [CrossRef]
  24. Groopman, J.D.; Smith, J.W.; Rivera-Andrade, A.; Alvarez, C.S.; Kroker-Lobos, M.F.; Egner, P.A.; Gharzouzi, E.; Dean, M.; McGlynn, K.A.; Ramírez-Zea, M. Aflatoxin and the aetiology of liver cancer and its implications for Guatemala. World Mycotoxin J. 2021, 14, 305–318. [Google Scholar] [CrossRef]
  25. McCoy, L.F.; Scholl, P.F.; Sutcliffe, A.E.; Kieszak, S.M.; Powers, C.D.; Rogers, H.S.; Gong, Y.Y.; Groopman, J.D.; Wild, C.P.; Schleicher, R.L. Human Aflatoxin Albumin Adducts Quantitatively Compared by ELISA, HPLC with Fluorescence Detection, and HPLC with Isotope Dilution Mass Spectrometry. Cancer Epidemiol. Biomark. Prev. 2008, 17, 1653–1657. [Google Scholar] [CrossRef]
  26. Strosnider, H.; Azziz-Baumgartner, E.; Banziger, M.; Bhat, R.V.; Breiman, R.; Brune, M.N.; DeCock, K.; Dilley, A.; Groopman, J.; Hell, K.; et al. Workgroup report: Public health strategies for reducing aflatoxin exposure in developing countries. Environ. Health Perspect. 2006, 114, 1898–1903. [Google Scholar] [CrossRef]
  27. Tong, Y.; Tonui, P.; Orang’o, O.; Zhang, J.; Maina, T.; Muthoka, K.; Groopman, J.; Smith, J.; Madeen, E.; Ermel, A.; et al. Association of plasma aflatoxin with persistent detection of oncogenic human papillomaviruses in cervical samples from Kenyan women enrolled in a longitudinal study. BMC Infect. Dis. 2023, 23, 377. [Google Scholar] [CrossRef]
  28. Zhang, J.; Orang’o, O.; Tonui, P.; Tong, Y.; Maina, T.; Kiptoo, S.; Muthoka, K.; Groopman, J.; Smith, J.; Madeen, E.; et al. Detection and Concentration of Plasma Aflatoxin is Associated with Detection of Oncogenic Human Papillomavirus in Kenyan Women. In Open Forum Infectious Diseases; Oxford University Press: Oxford, UK, 2019; Volume 6. [Google Scholar] [CrossRef]
  29. Solis-Martinez, O.; Monge, A.; Groopman, J.D.; McGlynn, K.A.; Romero-Martinez, M.; Palacios-Rojas, N.; Batis, C.; Lamadrid-Figueroa, H.; Riojas-Rodriguez, H.; Lajous, M. Maize consumption and circulating aflatoxin levels in Mexican middle- and older-aged adults: A cross-sectional analysis. Am. J. Clin. Nutr. 2024, 121, 454–462. [Google Scholar] [CrossRef] [PubMed]
  30. Monge, A.; Romero, M.; Groopman, J.D.; McGlynn, K.A.; Santiago-Ruiz, L.; Villalpando-Hernández, S.; Mannan, R.; Burke, S.M.; Remes-Troche, J.M.; Lajous, M. Aflatoxin exposure in adults in southern and eastern Mexico in 2018: A descriptive study. Int. J. Hyg. Environ. Health 2023, 253, 114249. [Google Scholar] [CrossRef]
  31. Chen, C.; Mitchell, N.J.; Gratz, J.; Houpt, E.R.; Gong, Y.; Egner, P.A.; Groopman, J.D.; Riley, R.T.; Showker, J.L.; Svensen, E.; et al. Exposure to aflatoxin and fumonisin in children at risk for growth impairment in rural Tanzania. Environ. Int. 2018, 115, 29–37. [Google Scholar] [CrossRef]
  32. Chen, C.; Patil, C.L.; Mduma, E.R.; Groopman, J.D.; Riley, R.T.; Wu, F. Mycotoxins were not associated with environmental enteropathy in a cohort of Tanzanian children. Risk Anal. 2023, 43, 860–866. [Google Scholar] [CrossRef]
  33. Nyikal, J.; Misore, A.; Nzioka, C.; Njuguna, C. Outbreak of Aflatoxin Poisoning—Eastern and Central Provinces, Kenya, January–July 2004; 0149–2195; U.S. Center for Disease Control: Atlanta, GA, USA, 2004; p. 790.
  34. Azziz-Baumgartner, E.; Lindblade, K.; Gieseker, K.; Helen Schurz, R.; Kieszak, S.; Njapau, H. Case-Control Study of an Acute Aflatoxicosis Outbreak, Kenya, 2004. Environ. Health Perspect. 2005, 113, 1779–1783. [Google Scholar] [CrossRef] [PubMed]
  35. Probst, C.; Njapau, H.; Cotty, P.J. Outbreak of an acute aflatoxicosis in Kenya in 2004: Identification of the causal agent. Appl. Environ. Microbiol. 2007, 73, 2762–2764. [Google Scholar] [CrossRef] [PubMed]
  36. Koshiol, J.; Gao, Y.T.; Dean, M.; Egner, P.; Nepal, C.; Jones, K.; Wang, B.; Rashid, A.; Luo, W.; Van Dyke, A.L.; et al. Association of Aflatoxin and Gallbladder Cancer. Gastroenterology 2017, 153, 488–494 e481. [Google Scholar] [CrossRef]
  37. Nogueira, L.; Foerster, C.; Groopman, J.; Egner, P.; Koshiol, J.; Ferreccio, C. Association of aflatoxin with gallbladder cancer in Chile. Jama 2015, 313, 2075–2077. [Google Scholar] [CrossRef]
  38. Twagiramungu, J.d.D.; Njoroge, D.; Mburu, M.; Duke, G. Effect of Nixtamalization on Aflatoxins, Functional and Acceptability of Maize from Mulindi, Rwanda. Eur. J. Agric. Food Sci. 2024, 6, 27–33. [Google Scholar] [CrossRef]
  39. Gilbert Sandoval, I.; Wesseling, S.; Rietjens, I.M.C.M. Aflatoxin B1 in nixtamalized maize in Mexico; occurrence and accompanying risk assessment. Toxicol. Rep. 2019, 6, 1135–1142. [Google Scholar] [CrossRef] [PubMed]
  40. Guzzon, F.; Arandia Rios, L.W.; Caviedes Cepeda, G.M.; Céspedes Polo, M.; Chavez Cabrera, A.; Muriel Figueroa, J.; Medina Hoyos, A.E.; Jara Calvo, T.W.; Molnar, T.L.; Narro León, L.A.; et al. Conservation and Use of Latin American Maize Diversity: Pillar of Nutrition Security and Cultural Heritage of Humanity. Agronomy 2021, 11, 172. [Google Scholar] [CrossRef]
  41. Bunny, S.M.; Umar, A.; Bhatti, H.S.; Honey, S.F. Aflatoxin risk in the era of climatic change-a comprehensive review. CABI Agric. Biosci. 2024, 5, 105. [Google Scholar] [CrossRef]
  42. Wall-Martínez, H.A.; Ramírez-Martínez, A.; Wesolek, N.; Brabet, C.; Rodríguez-Jimenes, G.C.; García-Alvarado, M.A.; Salgado-Cervantes, M.A.; Robles-Olvera, V.J.; Roudot, A.C. Statistical analysis of corn consumption for improved mycotoxin exposure estimates for the population of Veracruz City, Mexico. Food Addit. Contam. Part A 2017, 34, 864–879. [Google Scholar] [CrossRef]
  43. Zuki-Orozco, B.A.; Batres-Esquivel, L.E.; Ortiz-Pérez, M.D.; Juárez-Flores, B.I.; Díaz-Barriga, F. Aflatoxins Contamination in Maize Products from Rural Communities in San Luis Potosi, Mexico. Ann. Glob. Health 2018, 84, 300–305. [Google Scholar] [CrossRef]
  44. Alvarez, C.S.; Rivera-Andrade, A.; Kroker-Lobos, M.F.; Florio, A.A.; Smith, J.W.; Egner, P.A.; Freedman, N.D.; Lazo, M.; Guallar, E.; Dean, M.; et al. Associations between aflatoxin B-albumin adduct levels with metabolic conditions in Guatemala: A cross-sectional study. Health Sci. Rep. 2022, 5, e495. [Google Scholar] [CrossRef]
  45. Kroker-Lobos, M.F.; Alvarez, C.S.; Rivera-Andrade, A.; Smith, J.W.; Egner, P.; Torres, O.; Lazo, M.; Freedman, N.D.; Guallar, E.; Graubard, B.I.; et al. Association between aflatoxin-albumin adduct levels and tortilla consumption in Guatemalan adults. Toxicol. Rep. 2019, 6, 465–471. [Google Scholar] [CrossRef]
  46. Garsow, A.V.; Torres, O.R.; Matute, J.A.; Voss, D.M.; Miyagusuku-Cruzado, G.; Giusti, M.M.; Kowalcyk, B.B. Dietary, socioeconomic, and maize handling practices associated with aflatoxin and fumonisin exposure among women tortilla makers in 5 departments in Guatemala. PLoS Glob. Public Health 2024, 4, e0001623. [Google Scholar] [CrossRef]
  47. Cabrera-Meraz, J.; Maldonado, L.; Bianchini, A.; Espinal, R. Incidence of aflatoxins and fumonisins in grain, masa and corn tortillas in four municipalities in the department of Lempira, Honduras. Heliyon 2021, 7, e08506. [Google Scholar] [CrossRef]
  48. Ranum, P.; Peña-Rosas, J.P.; Garcia-Casal, M.N. Global maize production, utilization, and consumption. Ann. N. Y. Acad. Sci. 2014, 1312, 105–112. [Google Scholar] [CrossRef] [PubMed]
  49. McGlynn, K.A.; Petrick, J.L.; Groopman, J.D. Liver Cancer: Progress and Priorities. Cancer Epidemiol. Biomark. Prev. 2024, 33, 1261–1272. [Google Scholar] [CrossRef]
  50. International Agency for Research on Cancer. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs (Vols 1–42); International Agency for Research on Cancer: Lyon, France, 1987.
  51. Wang, L.-Y.; Hatch, M.; Chen, C.-J.; Levin, B.; You, S.-L.; Lu, S.-N.; Wu, M.-H.; Wu, W.-P.; Wang, L.-W.; Wang, Q.; et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer 1996, 67, 620–625. [Google Scholar] [CrossRef]
  52. Cao, W.; Pan, Y.; Yang, K.; Cao, D. Aflatoxin B1: Metabolism, toxicology, and its involvement in oxidative stress and cancer development. Toxicol. Mech. Methods 2022, 32, 395–419. [Google Scholar] [CrossRef]
  53. Rayapati, D.; McGlynn, K.A.; Groopman, J.D.; Kim, A.K. Environmental exposures and the risk of hepatocellular carcinoma. Hepatol. Commun. 2025, 9, e0627. [Google Scholar] [CrossRef] [PubMed]
  54. Benkerroum, N. Chronic and Acute Toxicities of Aflatoxins: Mechanisms of Action. Int. J. Environ. Res. Public Health 2020, 17, 423. [Google Scholar] [CrossRef]
  55. Groopman, J.D. Changing Etiology and Epidemiology of Human Liver Cancer. In Liver Cancer in the Middle East; Carr, B.I., Ed.; Springer International Publishing: Cham, Switzerland, 2021; pp. 13–29. [Google Scholar]
  56. Chu, Y.J.; Yang, H.I.; Wu, H.C.; Lee, M.H.; Liu, J.; Wang, L.Y.; Lu, S.N.; Jen, C.L.; You, S.L.; Santella, R.M.; et al. Aflatoxin B(1) exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption. Eur. J. Cancer 2018, 94, 37–46. [Google Scholar] [CrossRef]
  57. Díaz, L.A.; Ayares, G.; Arnold, J.; Idalsoaga, F.; Corsi, O.; Arrese, M.; Arab, J.P. Liver Diseases in Latin America: Current Status, Unmet Needs, and Opportunities for Improvement. Curr. Treat. Options Gastroenterol. 2022, 20, 261–278. [Google Scholar] [CrossRef]
  58. Ross, R.K.; Yu, M.C.; Henderson, B.E.; Yuan, J.M.; Qian, G.S.; Tu, J.T.; Gao, Y.T.; Wogan, G.N.; Groopman, J.D. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992, 339, 943–946. [Google Scholar] [CrossRef]
  59. Haddad, L.; Gadano, A. HBV elimination in Central and South America: Current status and challenges. Clin. Liver Dis. 2024, 23, e0226. [Google Scholar] [CrossRef]
  60. Albala, C.; Vio, F. Obesity and Diabetes in Latin America: The Impact of Socioeconomic Status on Programs and Outcomes. In Global Challenges in Cardiovascular Prevention in Populations with Low Socioeconomic Status; Romero, T., Nazal, C.N., Lanas, F., Eds.; Springer Nature: Cham, Switzerland, 2025; pp. 51–61. [Google Scholar]
  61. Myers, S.; Neyroud-Caspar, I.; Spahr, L.; Gkouvatsos, K.; Fournier, E.; Giostra, E.; Magini, G.; Frossard, J.L.; Bascaron, M.E.; Vernaz, N.; et al. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep. 2021, 3, 100231. [Google Scholar] [CrossRef] [PubMed]
  62. Ssentongo, P.; Ssentongo, A.E.; Ba, D.M.; Ericson, J.E.; Na, M.; Gao, X.; Fronterre, C.; Chinchilli, V.M.; Schiff, S.J. Global, regional and national epidemiology and prevalence of child stunting, wasting and underweight in low- and middle-income countries, 2006–2018. Sci. Rep. 2021, 11, 5204. [Google Scholar] [CrossRef] [PubMed]
  63. Voth-Gaeddert, L.E.; Torres, O.; Maldonado, J.; Krajmalnik-Brown, R.; Rittmann, B.E.; Oerther, D.B. Aflatoxin exposure, child stunting, and dysbiosis in the intestinal microbiome among children in Guatemala. Environ. Eng. Sci. 2019, 36, 958–968. [Google Scholar] [CrossRef]
  64. Rasheed, H.; Xu, Y.; Kimanya, M.E.; Pan, X.; Li, Z.; Zou, X.; Shirima, C.P.; Holmes, M.; Routledge, M.N.; Gong, Y.Y. Estimating the health burden of aflatoxin attributable stunting among children in low income countries of Africa. Sci. Rep. 2021, 11, 1619. [Google Scholar] [CrossRef]
  65. Matchado, A.; Smith, J.W.; Schulze, K.J.; Groopman, J.D.; Kortekangas, E.; Chaima, D.; Arnold, C.D.; Maleta, K.; Ashorn, U.; Ashorn, P.; et al. Child Aflatoxin Exposure is Associated with Poor Child Growth Outcomes: A Prospective Cohort Study in Rural Malawi. Curr. Dev. Nutr. 2023, 7, 101962. [Google Scholar] [CrossRef] [PubMed]
  66. Gong, Y.Y.; Watson, S.; Routledge, M.N. Aflatoxin Exposure and Associated Human Health Effects, a Review of Epidemiological Studies. Food Saf. 2016, 4, 14–27. [Google Scholar] [CrossRef]
  67. Turner, P.C.; Moore, S.E.; Hall, A.J.; Prentice, A.M.; Wild, C.P. Modification of immune function through exposure to dietary aflatoxin in Gambian children. Environ. Health Perspect. 2003, 111, 217–220. [Google Scholar] [CrossRef]
  68. Jiang, Y.; Jolly, P.E.; Ellis, W.O.; Wang, J.S.; Phillips, T.D.; Williams, J.H. Aflatoxin B1 albumin adduct levels and cellular immune status in Ghanaians. Int. Immunol. 2005, 17, 807–814. [Google Scholar] [CrossRef]
  69. Carvajal, M.; Berumen, J.; Guardado-Estrada, M. The presence of aflatoxin B1-FAPY adduct and human papilloma virus in cervical smears from cancer patients in Mexico. Food Addit. Contam. Part. A 2012, 29, 258–268. [Google Scholar] [CrossRef]
  70. de León-Martínez, L.D.; López-Mendoza, C.; Terán-Figueroa, Y.; Flores-Ramírez, R.; Díaz-Barriga, F.; Alcántara-Quintana, L. Detection of aflatoxin B1 adducts in Mexican women with cervical lesions. World Mycotoxin J. 2021, 14, 327–338. [Google Scholar] [CrossRef]
  71. Koshiol, J.; Hildesheim, A.; Zhu, B.; Wang, R.; Gao, Y.; Egner, P.; Yuan, J.; Groopman, J. Longitudinal analysis of aflatoxin and gallbladder cancer. HPB 2019, 21, S20–S21. [Google Scholar] [CrossRef]
  72. Koshiol, J.; Zhu, B.; Wang, R.; Hildesheim, A.; Gao, Y.T.; Egner, P.A.; Yuan, J.M.; Groopman, J.D. Association of aflatoxin with gallbladder cancer in a case-control study nested within a Chinese cohort. Int. J. Cancer 2024, 154, 801–806. [Google Scholar] [CrossRef]
  73. Dai, C.; Tian, E.; Li, H.; Das Gupta, S.; Hao, Z.; Wang, Z.; Velkov, T.; Shen, J. Molecular mechanisms of aflatoxin neurotoxicity and potential neuroprotective agents. Food Sci. Hum. Wellness 2024, 13, 2445–2455. [Google Scholar] [CrossRef]
  74. Mitchell, N.J.; Kumi, J.; Johnson, N.M.; Dotse, E.; Marroquin-Cardona, A.; Wang, J.S.; Jolly, P.E.; Ankrah, N.-A.; Phillips, T.D. Reduction in the urinary aflatoxin M1 biomarker as an early indicator of the efficacy of dietary interventions to reduce exposure to aflatoxins. Biomarkers 2013, 18, 391–398. [Google Scholar] [CrossRef]
  75. Skipper, P.L.; Tannenbaum, S.R. Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis 1990, 11, 507–518. [Google Scholar] [CrossRef]
  76. Stutt, R.O.J.H.; Castle, M.D.; Markwell, P.; Baker, R.; Gilligan, C.A. An integrated model for pre- and post-harvest aflatoxin contamination in maize. Npj Sci. Food 2023, 7, 60. [Google Scholar] [CrossRef]
  77. Dövényi-Nagy, T.; Rácz, C.; Molnár, K.; Bakó, K.; Szláma, Z.; Jóźwiak, Á.; Farkas, Z.; Pócsi, I.; Dobos, A.C. Pre-Harvest Modelling and Mitigation of Aflatoxins in Maize in a Changing Climatic Environment—A Review. Toxins 2020, 12, 768. [Google Scholar] [CrossRef] [PubMed]
  78. Peles, F.; Sipos, P.; Kovács, S.; Győri, Z.; Pócsi, I.; Pusztahelyi, T. Biological Control and Mitigation of Aflatoxin Contamination in Commodities. Toxins 2021, 13, 104. [Google Scholar] [CrossRef]
  79. Ortega-Beltran, A.; Bandyopadhyay, R. Aflatoxin biocontrol in practice requires a multidisciplinary, long-term approach. Front. Sustain. Food Syst. 2023, 7, 1110964. [Google Scholar] [CrossRef]
  80. Alaniz Zanon, M.S.; Bossa, M.; Chiotta, M.L.; Oddino, C.; Giovanini, D.; Cardoso, M.L.; Bartosik, R.E.; Chulze, S.N. Pre-harvest strategy for reducing aflatoxin accumulation during storage of maize in Argentina. Int. J. Food Microbiol. 2022, 380, 109887. [Google Scholar] [CrossRef]
  81. Kortei, N.K.; Osei, S.; Addae, A.A.; Akonor, P.T.; Manaphraim, N.Y.B.; Annan, T. Impact of some Ghanaian local roasting methods on aflatoxin reduction in groundnuts (Arachis hypogaea L). Sci. Afr. 2024, 23, e02022. [Google Scholar] [CrossRef]
  82. Romero-Sánchez, I.; Gracia-Lor, E.; Madrid-Albarrán, Y. Aflatoxin detoxification by thermal cooking treatment and evaluation of in vitro bioaccessibility from white and brown rice. Food Chem. 2024, 436, 137738. [Google Scholar] [CrossRef]
  83. Montenegro-Benthancourt, G.; Glesener, H.; Torres, O.; Seegmiller, E.; Rohloff, P.; Voth-Gaeddert, L.E. Practices of maize handling and nixtamalization to reduce fungal toxin exposure in rural Guatemala. J. Agric. Food Res. 2024, 18, 101512. [Google Scholar] [CrossRef]
  84. Deng, J.; Zhao, L.; Zhang, N.-Y.; Karrow, N.A.; Krumm, C.S.; Qi, D.-S.; Sun, L.-H. Aflatoxin B1 metabolism: Regulation by phase I and II metabolizing enzymes and chemoprotective agents. Mutat. Res./Rev. Mutat. Res. 2018, 778, 79–89. [Google Scholar] [CrossRef] [PubMed]
  85. Kensler, T.W.; Chen, J.G.; Egner, P.A.; Fahey, J.W.; Jacobson, L.P.; Stephenson, K.K.; Ye, L.; Coady, J.L.; Wang, J.B.; Wu, Y.; et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People’s Republic of China. Cancer Epidemiol. Biomark. Prev. 2005, 14, 2605–2613. [Google Scholar] [CrossRef]
  86. Chen, J.-G.; Zhu, Y.-R.; Qian, G.-S.; Wang, J.-B.; Lu, J.-H.; Kensler, T.W.; Jacobson, L.P.; Muñoz, A.; Groopman, J.D. Fifty Years of Aflatoxin Research in Qidong, China: A Celebration of Team Science to Improve Public Health. Toxins 2025, 17, 79. [Google Scholar] [CrossRef]
  87. Wang, J.S.; Shen, X.; He, X.; Zhu, Y.R.; Zhang, B.C.; Wang, J.B.; Qian, G.S.; Kuang, S.Y.; Zarba, A.; Egner, P.A.; et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People’s Republic of China. J. Natl. Cancer Inst. 1999, 91, 347–354. [Google Scholar] [CrossRef] [PubMed]
  88. Jacobson, L.P.; Zhang, B.C.; Zhu, Y.R.; Wang, J.B.; Wu, Y.; Zhang, Q.N.; Yu, L.Y.; Qian, G.S.; Kuang, S.Y.; Li, Y.F.; et al. Oltipraz chemoprevention trial in Qidong, People’s Republic of China: Study design and clinical outcomes. Cancer Epidemiol. Biomark. Prev. 1997, 6, 257–265. [Google Scholar]
  89. Wang, X.; Wang, T.; Nepovimova, E.; Long, M.; Wu, W.; Kuca, K. Progress on the detoxification of aflatoxin B1 using natural anti-oxidants. Food Chem. Toxicol. 2022, 169, 113417. [Google Scholar] [CrossRef]
Toxins 18 00058 g001
Figure 1. Graphical representation of daily aflatoxin exposure in µg for studies in Kenya (2005) [25,26]; Guangxi, Fusui, and Qidong [17,21]; Guatemala [23,24]; Mexico [29,30]; Chile [36,37]; cirrhosis in Guatemala [22]; Malawi [18]; Bangladesh [18,19,20]; Kenyan women [27,28]; and Tanzanian children [31,32]. The area highlighted represents the 1 μg to 5 μg per day range where many human health effects have been documented. The open circles represent individual data points that are either below the 5th percentile or above the 95th percentile.
Figure 1. Graphical representation of daily aflatoxin exposure in µg for studies in Kenya (2005) [25,26]; Guangxi, Fusui, and Qidong [17,21]; Guatemala [23,24]; Mexico [29,30]; Chile [36,37]; cirrhosis in Guatemala [22]; Malawi [18]; Bangladesh [18,19,20]; Kenyan women [27,28]; and Tanzanian children [31,32]. The area highlighted represents the 1 μg to 5 μg per day range where many human health effects have been documented. The open circles represent individual data points that are either below the 5th percentile or above the 95th percentile.
Toxins 18 00058 g001
Table 1. Estimated daily aflatoxin exposure by regulatory limits and intake of contaminated foods.
Table 1. Estimated daily aflatoxin exposure by regulatory limits and intake of contaminated foods.
Contaminated Food Consumption Level per Day (g)Total Aflatoxins Regulatory Limits (ppb)Estimated Aflatoxin Intake (ug)
2540.10
100.25
150.38
200.50
5040.20
100.50
150.75
201.00
10040.40
101.00
151.50
202.00
25041.00
102.50
153.75
205.00
35041.40
103.50
155.25
207.00
Table 2. Daily aflatoxin exposure (µg) for various studies.
Table 2. Daily aflatoxin exposure (µg) for various studies.
CountryYearDetailsnAflatoxin (SD)95% CIMin.Max.%ND *Ref.
Bangladesh2008–2011Preg. women 1st trimester630.35 (0.22)(0.29, 0.41)ND1.146.4[18,19,20]
Preg. women 3rd trimester630.48 (0.25)(0.42, 0.55)ND1.311.6
Cord blood630.51 (0.27)(0.44, 0.57)0.081.380
Child 24 mos.630.37 (0.30)(0.30, 0.45)ND1.471.6
China1982Guangxi764.01 (8.30)(2.11, 5.91)0.1744.380[17,21]
1983Fusui311.55 (1.40)(1.04, 2.06)ND5.663.2
1989Qidong741.20 (0.88)(1.00, 1.40)0.114.660
1995Qidong1000.33 (0.52)(0.22, 0.43)ND3.792
1999Qidong1000.20 (0.19)(0.16, 0.23)ND1.128
2003Qidong1000.10 (0.12)(0.08, 0.13)ND0.624
2009Qidong1000.06 (0.14)(0.03, 0.09)ND0.8177
2012Qidong1000.01 (0.02)(0.01, 0.02)ND0.1692
Guatemala2015Cirrhosis cases991.18 (1.54)(0.87, 1.49)ND9.521[22]
Controls2000.67 (1.11)(0.52, 0.83)0.037.620
2016Escuintla937.73 (12.82)(5.09, 10.37)ND87.384.3[23,24]
Mixco601.50 (2.06)(0.97, 2.03)0.0611.570
Sololá601.97 (3.13)(1.16, 2.78)0.1823.510
Suchitepéquez822.02 (2.43)(1.49, 2.56)0.0916.120
Quiche1011.33 (4.93)(0.36, 2.31)ND45.21
Kenya2005Aflatoxicosis outbreak5591.1 (201.42)(36.65, 145.55)1.11981.10[25,26]
2015–2016Women baseline1201.93 (1.95)(1.58, 2.29)0.1310.610[27,28]
Women 12-mo. follow-up1151.55 (1.62)(1.25, 1.85)0.1411.930
Malawi2011–2015Preg. women baseline2551.04 (1.43)(0.87, 1.22)ND15.574.7[18]
Preg. women GA 36 wks.2551.20 (1.77)(0.98, 1.41)ND10.734.7
Women 6 mos. postpartum2301.86 (3.31)(1.43, 2.29)0.0425.040
Infant 6 mos. old2300.41 (1.00)(0.28, 0.54)ND8.5343.5
Infant 18 mos. old2311.49 (4.98)(0.85, 2.14)ND69.288.7
Mexico2018–2019South and eastern Mexico8551.03 (3.77)(0.78, 1.28)0.0176.230[29,30]
Tanzania2018Haydom (rural)5451.76 (3.00)(1.51, 2.02)ND42.980.2[31,32]
Aflatoxin is represented in µg/day; calculations were estimated from plasma serum AFB1-albumin adducts. Abbreviations: pregnant (Preg.), month (mo.), months (mos.), gestational age (GA), standard deviation (SD), confidence interval (CI), nondetectable (ND), minimum (Min.), maximum (Max.), and references (refs.). * ND = nondetectable.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Corleto, K.A.; Alvarez, C.S.; Ramirez-Zea, M.; Groopman, J.D.; McGlynn, K.A. Aflatoxin Exposure and Human Health with a Focus on Northern Latin America. Toxins 2026, 18, 58. https://doi.org/10.3390/toxins18010058

AMA Style

Corleto KA, Alvarez CS, Ramirez-Zea M, Groopman JD, McGlynn KA. Aflatoxin Exposure and Human Health with a Focus on Northern Latin America. Toxins. 2026; 18(1):58. https://doi.org/10.3390/toxins18010058

Chicago/Turabian Style

Corleto, Karen A., Christian S. Alvarez, Manuel Ramirez-Zea, John D. Groopman, and Katherine A. McGlynn. 2026. "Aflatoxin Exposure and Human Health with a Focus on Northern Latin America" Toxins 18, no. 1: 58. https://doi.org/10.3390/toxins18010058

APA Style

Corleto, K. A., Alvarez, C. S., Ramirez-Zea, M., Groopman, J. D., & McGlynn, K. A. (2026). Aflatoxin Exposure and Human Health with a Focus on Northern Latin America. Toxins, 18(1), 58. https://doi.org/10.3390/toxins18010058

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop